ARDELYX, INC.
Ardelyx Inc. (ARDX) shares rose 2% after-hours, reaffirming 2026 guidance for IBSRELA and XPHOZAH, targeting $500M+ revenue this year. The company expects $1B IBSRELA sales by 2029 and $750M peak for XPHOZAH. Profitability is anticipated soon, with operating expenses guided at $520M. Analysts rate ARDX 'Buy' with a 12-month average price target of $16.33, implying over 200% upside.
RAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.
Ardelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ARDX (ARDELYX, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ARDX coverage spans earnings, corporate actions and insider activity.
In the last 30 days, ARDX insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($486K). The most active reporter was Williams Laura A, Chief Patient Officer, with 4 filings.
Guidance reaffirmation supports near‑term upside, but higher operating expenses may temper enthusiasm.
Insider sale by the chief executive may signal reduced confidence or portfolio rebalancing.
Minor dilution and supply increase; unlikely to move price materially.
Guidance reset increases near-term revenue risk while reaffirming XPHOZAH momentum and pushing key clinical readouts into 2H27.
The article links a sharp selloff in ARDX to a surge in put-heavy options activity, suggesting elevated downside hedging and bearish positioning.
AlphAI scores every news story that mentions ARDX with an AI model for sentiment and relevance, and aggregates insider trades from ARDELYX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ardelyx Inc. (ARDX) shares rose 2% after-hours, reaffirming 2026 guidance for IBSRELA and XPHOZAH, targeting $500M+ revenue this year. The company expects $1B IBSRELA sales by 2029 and $750M peak for XPHOZAH. Profitability is anticipated soon, with operating expenses guided at $520M. Analysts rate ARDX 'Buy' with a 12-month average price target of $16.33, implying over 200% upside.
1 min readRAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.
1 min readArdelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.
1 min readArdelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.
6 min readAccording to exchange data compiled by Bloomberg and reported by Investing.com, Ardelyx Inc. options activity rose Friday morning to 11,147 contracts, with puts dominating (10,676). The October 16, 2026 $4 put led with 10,004 contracts. Ardelyx shares fell 18.4% to $3.98, and 3-month volatility rose to 74.93%.
2 min readArdelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
4 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow
5 min readInsider Monkey’s “Claude Portfolio” account says Ardelyx (NASDAQ:ARDX) is undervalued versus an earnings turnaround. It cites a 58% rise in Ibsrela sales last quarter, a goal of $1B annual sales by 2029, and consensus EPS moving from breakeven in 2026 to about $0.52 in 2027. ARDX trades near $5.14; risks include delayed profits, dilution, and Medicare reimbursement pressure after an appeal loss for Xphozah.
6 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ardx-20260629 0001437402 false 0001437402 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ardx-20260616 0001437402 false 0001437402 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min read
